These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 15980409)

  • 1. Specific antibodies, levofloxacin, and modulation of capsule-associated virulence in Streptococcus pneumoniae.
    Tarragó D; Lara N; Fenoll A; Casal J; Giménez MJ; Aguilar L; Sevillano D
    Antimicrob Agents Chemother; 2005 Jul; 49(7):3095-6. PubMed ID: 15980409
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I; Cars O
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virulence of Streptococcus pneumoniae may be determined independently of capsular polysaccharide.
    Mizrachi Nebenzahl Y; Porat N; Lifshitz S; Novick S; Levi A; Ling E; Liron O; Mordechai S; Sahu RK; Dagan R
    FEMS Microbiol Lett; 2004 Apr; 233(1):147-52. PubMed ID: 15043881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drastic reduction in the virulence of Streptococcus pneumoniae expressing type 2 capsular polysaccharide but lacking choline residues in the cell wall.
    Kharat AS; Tomasz A
    Mol Microbiol; 2006 Apr; 60(1):93-107. PubMed ID: 16556223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capsule does not block antibody binding to PspA, a surface virulence protein of Streptococcus pneumoniae.
    Daniels CC; Briles TC; Mirza S; Håkansson AP; Briles DE
    Microb Pathog; 2006 May; 40(5):228-33. PubMed ID: 16540281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial sinus aspirate samples during high-dose, short-course levofloxacin treatment of acute maxillary sinusitis.
    Anon JB; Paglia M; Xiang J; Ambrose PG; Jones RN; Kahn JB
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):105-7. PubMed ID: 17178300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etest compared to broth microdilution: discrepant results when testing macrolides against Streptococcus pneumoniae indicate a need for better clinical and serum level/MIC correlation.
    Sader H; Del'Alamo L
    Braz J Infect Dis; 2000 Oct; 4(5):268-70. PubMed ID: 11063559
    [No Abstract]   [Full Text] [Related]  

  • 8. In vivo development of high-level fluoroquinolone resistance in Streptococcus pneumoniae in chronic obstructive pulmonary disease.
    Pérez-Trallero E; Marimón JM; González A; Ercibengoa M; Larruskain J
    Clin Infect Dis; 2005 Aug; 41(4):560-4. PubMed ID: 16028169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct approaches to investigate the importance of the murine 4-1BB 4-1BBL interaction in the antibody response to Streptococcus pneumoniae.
    Moens L; Jeurissen A; Mittler RS; Wuyts G; Michiels G; Boon L; Ceuppens JL; Bossuyt X
    J Leukoc Biol; 2007 Sep; 82(3):638-44. PubMed ID: 17550973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Splenic autotransplantation restores IL-17 production and antibody response to Streptococcus pneumoniae in splenectomized mice.
    Fernandes BF; Rezende AB; Alves CC; Teixeira FM; Farias RE; Ferreira AP; Teixeira HC
    Transpl Immunol; 2010 Feb; 22(3-4):195-7. PubMed ID: 20036332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Call for the international adoption of microbiological breakpoints for fluoroquinolones and Streptococcus pneumoniae.
    Schurek KN; Adam HJ; Hoban DJ; Zhanel GG
    Int J Antimicrob Agents; 2006 Sep; 28(3):266-9. PubMed ID: 16904294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Contributions of putative lipoate-protein ligase to the virulence of Streptococcus pneumoniae].
    Yang X; Yin N; Pang D; Wu K; Yin Y; Zhang X
    Wei Sheng Wu Xue Bao; 2010 Jun; 50(6):774-9. PubMed ID: 20687343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Requirement for capsule in colonization by Streptococcus pneumoniae.
    Magee AD; Yother J
    Infect Immun; 2001 Jun; 69(6):3755-61. PubMed ID: 11349040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of high dose oral zinc in mice with severe infection with Streptococcus pneumoniae.
    Hembre BS; Briles DE; Grewal HM; Strand TA
    Scand J Infect Dis; 2008; 40(5):363-7. PubMed ID: 17963160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
    Tillotson GS; Zhao X; Drlica K
    N Engl J Med; 2002 Jul; 347(1):65-7; author reply 65-7. PubMed ID: 12102062
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae.
    Lister PD
    Postgrad Med; 2008 Sep; 120(3 Suppl 1):46-52. PubMed ID: 18931471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Lysozyme activity of pneumococci].
    Bukharin OV; Prianishnikova LI; Usviatsov BIa
    Antibiotiki; 1978 Dec; 23(12):1094-7. PubMed ID: 31835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
    Hutchinson J
    N Engl J Med; 2002 Jul; 347(1):65-7; author reply 65-7. PubMed ID: 12102064
    [No Abstract]   [Full Text] [Related]  

  • 19. Pneumococcal infection and pneumococcal vaccine.
    Austrian R
    N Engl J Med; 1977 Oct; 297(17):938-9. PubMed ID: 20576
    [No Abstract]   [Full Text] [Related]  

  • 20. Activity of nisin against Streptococcus pneumoniae, in vitro, and in a mouse infection model.
    Goldstein BP; Wei J; Greenberg K; Novick R
    J Antimicrob Chemother; 1998 Aug; 42(2):277-8. PubMed ID: 9738856
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.